These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17674979)

  • 101. [Proton beam therapy combined with chemotherapy for advanced cancer].
    Fuwa N
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1385-9. PubMed ID: 21918332
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Early-onset dropped head syndrome after radiotherapy for head and neck cancer: dose constraints for neck extensor muscles.
    Inaba K; Nakamura S; Okamoto H; Kashihara T; Kobayashi K; Harada K; Kitaguchi M; Sekii S; Takahashi K; Murakami N; Ito Y; Igaki H; Uno T; Itami J
    J Radiat Res; 2016 Mar; 57(2):169-73. PubMed ID: 26684338
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Radiation oncology research in the cancer and leukemia group B.
    Bogart JA; Seagren SL; Glicksman A
    Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3628s-34s. PubMed ID: 16740797
    [TBL] [Abstract][Full Text] [Related]  

  • 104. [Contribution to survival rate improvement].
    Hatano K; Sakai M; Araki H; Imagunbai T
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1833-6. PubMed ID: 19011331
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Applying radiobiological principles to combined modality treatment of head and neck cancer--the time factor.
    Peters LJ; Withers HR
    Int J Radiat Oncol Biol Phys; 1997 Nov; 39(4):831-6. PubMed ID: 9369130
    [TBL] [Abstract][Full Text] [Related]  

  • 106. A Review of Modern Radiation Therapy Dose Escalation in Locally Advanced Head and Neck Cancer.
    Atwell D; Elks J; Cahill K; Hearn N; Vignarajah D; Lagopoulos J; Min M
    Clin Oncol (R Coll Radiol); 2020 May; 32(5):330-341. PubMed ID: 31911016
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Head and neck oncology: what the past decade has taught us.
    Bernier J
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1133-6. PubMed ID: 17020448
    [No Abstract]   [Full Text] [Related]  

  • 108. The need for adverse effects reporting standards in oncology clinical trials.
    Trotti A; Bentzen SM
    J Clin Oncol; 2004 Jan; 22(1):19-22. PubMed ID: 14657230
    [No Abstract]   [Full Text] [Related]  

  • 109. Testing new chemoradiation regimens for head-and-neck cancer.
    Eisbruch A; Normolle DP
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):5-6. PubMed ID: 15629586
    [No Abstract]   [Full Text] [Related]  

  • 110. [Evidence-based medicine (EBM) for radiation therapy--head and neck cancer].
    Sakata K
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):334-8. PubMed ID: 12669389
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Early skin reactions in head and neck malignancy treated by twice-daily fractionated radiotherapy--estimation of alpha/beta of LQ model.
    Chougule A; Supe SJ
    Phys Med Biol; 1993 Sep; 38(9):1335-42. PubMed ID: 8415904
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Revised Modelling of the Addition of Synchronous Chemotherapy to Radiotherapy in Squamous Cell Carcinoma of the Head and Neck-A Low
    Best J; Fong C; Benghiat H; Mehanna H; Glaholm J; Hartley A
    Medicines (Basel); 2018 Jun; 5(2):. PubMed ID: 29899241
    [No Abstract]   [Full Text] [Related]  

  • 113. [Current status of phase III study of combined treatment with radiotherapy and chemotherapy for head and neck cancer].
    Inoue T; Inoue T; Murayama S
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):350-6. PubMed ID: 7880105
    [TBL] [Abstract][Full Text] [Related]  

  • 114. At last--progress in the assessment of the adverse effects of cancer treatments.
    Horiot JC
    Lancet Oncol; 2007 Jul; 8(7):568-70. PubMed ID: 17613419
    [No Abstract]   [Full Text] [Related]  

  • 115. In regard to Staar et al.: Intensified hyperfractionated accelerated radiotherapy limits the additional benefits of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. IJROBP 2001;50:1161-1171.
    Grabenbauer GG; Sauer R
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):300. PubMed ID: 12183004
    [No Abstract]   [Full Text] [Related]  

  • 116. 21 years of biologically effective dose.
    Fowler JF
    Br J Radiol; 2010 Jul; 83(991):554-68. PubMed ID: 20603408
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Curie medal lecture 2000. The optimization of delivered dose in radiotherapy: is it related to low dose rate?
    Pierquin B
    Radiother Oncol; 2001 Jan; 58(1):7-9. PubMed ID: 11165675
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Cytotoxic Effect of Erythroxylum suberosum Combined with Radiotherapy in Head and Neck Cancer Cell Lines.
    Macedo TB; Elias ST; Torres HM; Yamamoto-Silva FP; Silveira D; Magalhães PO; Lofrano-Porto A; Guerra EN; Silva MA
    Braz Dent J; 2016; 27(1):108-12. PubMed ID: 27007356
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Mucosal regeneration during radiotherapy. Trans Tasman Radiation Oncology Group (TROG).
    Denham JW; Walker QJ; Lamb DS; Hamilton CS; O'Brien PC; Spry NA; Hindley A; Poulsen M; O'Brien M; Tripcony L
    Radiother Oncol; 1996 Nov; 41(2):109-18. PubMed ID: 9004352
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Progress in radiotherapy by treatment tailoring in head and neck cancer.
    Bartelink H; Keus RB
    Curr Opin Oncol; 1991 Jun; 3(3):523-8. PubMed ID: 1892922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.